COMMUNIQUÉS West-GlobeNewswire

Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks Conference
31/01/2024
IRVINE, Calif., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients [...]
Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine
31/01/2024
Data reinforce the potential of NTLA-2002 to eliminate angioedema attacks in people living with hereditary angioedema (HAE) after a single dose A single dose of NTLA-2002 led to 95% mean reduction in monthly HAE attack [...]
Vision Sensing Acquisition Corp. Announces Intention to Extend Period to Consummate Initial Business Combination to March 3, 2024
31/01/2024
MIAMI, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) (the “Company”) a special purpose acquisition company, announced today that it has notified Continental Stock [...]
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
31/01/2024
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 31, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of [...]
DLH Reports Fiscal 2024 First Quarter Results
31/01/2024
Further Debt Reduction and Strong Start to Fiscal Year ATLANTA, Jan. 31, 2024 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of science research and development, [...]
Ascendis Pharma to Report Full Year 2023 Financial Results and Provide Business Update on February 7, 2024
31/01/2024
COPENHAGEN, Denmark, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report full year 2023 financial results and provide a business update on Wednesday, February 7, 2024, [...]
Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference
31/01/2024
PARIS and CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand [...]
Nanobiotix participera à la 6ème conférence annuelle de Biotechnologie de Guggenheim
31/01/2024
PARIS and CAMBRIDGE, Mass., 31 janv. 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ : NBTX – la « Société » ), société française de biotechnologie en phase de développement clinique avancé, pionnière des [...]
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
31/01/2024
CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing treatments in high unmet need [...]
Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market
31/01/2024
BOSTON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that [...]
Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference
31/01/2024
WALTHAM, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living [...]
Ascendis Pharma Launches 2nd TransCon™ Product: YORVIPATH® Now Available in Germany and Austria for Adults with Chronic Hypoparathyroidism
31/01/2024
COPENHAGEN, Denmark, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that YORVIPATH ® (palopegteriparatide, developed as TransCon PTH), a parathyroid hormone (PTH) replacement [...]
Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option
31/01/2024
SAN DIEGO and TORONTO, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (Nasdaq: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated [...]
Galapagos completes transaction to transfer Jyseleca® business to Alfasigma
31/01/2024
Mechelen, Belgium; 31 January 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced the successful completion of the transaction to transfer its Jyseleca® (filgotinib) business to Alfasigma S.p.A. [...]
Compass Pathways to participate in upcoming Oppenheimer investor conference
31/01/2024
LONDON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that [...]
AHG Announces Plan to Acquire Online Clinic
31/01/2024
QINGDAO CHINA, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Akso Health Group (NASDAQ: AHG) ( "Akso Health," "the Company," or "we") today announced its plan to make an equity investment in Deyihui, an online clinic based in China [...]
Merus annonce la tenue d’une série de conférences auprès des investisseurs
31/01/2024
UTRECHT, Pays-Bas et CAMBRIDGE, Massachusetts, 31 janv. 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS), une société spécialisée dans l’oncologie au stade clinique développant des anticorps de pleine longueur [...]
SAFE - Lettre aux actionnaires
31/01/2024
Lettre aux actionnaires N°1 - Janvier 2024 La renaissance du Groupe SAFE Madame, Monsieur, Chers actionnaires, Permettez-nous de vous adresser nos meilleurs vœux pour cette nouvelle année. 2023 a été une année [...]
60 Degrees Pharmaceuticals Announces Closing of $2.4 Million Public Offering
31/01/2024
WASHINGTON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals , Inc. ( NASDAQ: SXTP; SXTPW ) (“60 Degrees Pharmaceuticals” or the “Company”), specialists in developing and marketing new medicines for the [...]

Pages